Gain Therapeutics, Inc. (GANX)
$1.64+1.23%Close
SELLCRISIS · day 9
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $70M
- Beta
- 0.19
- P/E (TTM)
- -3.34
- Short % float
- 7.34%
- Days to cover
- 5.9
- SI change
- +5.8%
- 1W
- -4.09%
- 1M
- -4.09%
- vs SPY 1W
- -5.25%
- vs SPY 1M
- -7.09%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on GANX?
- LOPJLB’s latest quantitative signal on Gain Therapeutics, Inc. (GANX) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is GANX in?
- Gain Therapeutics, Inc. (GANX) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Gain Therapeutics, Inc. (GANX) do?
- Gain Therapeutics, Inc. is a biotechnology firm specializing in the creation of advanced treatments for conditions originating from improperly folded proteins. The company primarily directs its efforts towards rare genetic disorders and neurological ailments. It employs its unique Site-Directed Enzyme Enhancement Therapy (SEE-Tx) platform to pinpoint specific allosteric sites on malformed prote…